CAJ | 학술논문

目的　观察脱氢表雄酮硫酸酯治疗男性骨质疏松症的疗效、安全性。方法　随机对照观察脱氢表雄酮硫酸酯服用6个月前后骨密度(BMD)、血生化指标、骨吸收指标和骨形成指标，副作用等方面的变化。结果　治疗后治疗组脱氢表雄酮硫酸酯(DS)、类胰岛素生长因子-I(IGF-I) 较治疗前分别提高(93.75±16.1)%、(17.71±4.2)%，较对照组明显提高(P<0.01) 。腰2、腰3、腰4的骨密度(BMD)较治疗前分别提高(2.65±0.62)%、(2.70±0.48)%、(3 .10±0.41)%，腰2～4较治疗前提高(2.82±0.37)%，股骨颈较治疗前提高(2.32±0. 31)%。腰2、腰3、腰4、腰2～4，股骨颈的BMD上升幅度较大与对照组比较有显著性差异( P<0.05，0.01)。对游离睾丸酮(FT)、雌二醇(E2)、前列腺特异抗原(PSA)则无明显影响。结论　脱氢表雄酮硫酸酯治疗男性骨质疏松症有较好疗效，且安全可靠，无不良反应。
목적　관찰탈경표웅동류산지치료남성골질소송증적료효、안전성。 방법　수궤대조관찰탈경표웅동류산지복용6개월전후골밀도(BMD)、혈생 화지표、골흡수지표화골형성지표，부작용등방면적변화。결과　치료후치료조탈경표웅동류산지(DS)、류이도소생장인자-I(IGF-I) 교치료전분별제고(93.75±16.1)%、(17.71±4.2)%，교대조조명현제고(P<0.01) 。요2、요3、요4적골밀도(BMD)교치료전분별제고(2.65±0.62)%、(2.70±0.48)%、(3 .10±0.41)%，요2～4교치료전제고(2.82±0.37)%，고골경교치료전제고(2.32±0. 31)%。요2、요3、요4、요2～4，고골경적BMD상승폭도교대여대조조비교유현저성차이( P<0.05，0.01)。대유리고환동(FT)、자이순(E2)、전렬선특이항원(PSA)칙무명현영 향。결론　탈경표웅동류산지치료남성골질소송증유교호료효，차안전가고，무불량반응。
Objective To study the efficacy and safety of dehydro epiandrosterone sulfate(DHEAS) in treatment of osteoporosis in males. Methods Eighty-six patients were divided randomly into two group s:the treatment group(n=44) and the control group(n=42). DHEAS 100mg qd was given to the treatment group for 6 months. BMD, biochemical markers of bone resorption and formation, and other serum biochemical markers were measured befo re and after DHEAS administration for 6 months. The side effects of the drug wer e also observed. Results The serum concentrations of DHEAS and IGF-1 were signif icantly increased in the treatment group, compared with the control group(93.75 ±16.1% versus 17.71±4.2%,P<0.01). The BMD of L2, L3,L4,L2-4 and Neck sections were increased in the treatment group, compared with control group(2.6 5 ±0.65%,2.70±0.48%，3.10±0.41%,2.82±0.37% and 2.32±0.31% respective ly, P<0.05 or 0.01). No significant changes in serum FT, E2 and PSA concen trations were found in the treatment group, compared with the control group. Conclusion Treatment of osteoporosis in males with DHEAS is safe a nd effective.